Mirvetuximab Soravtansine Exposure and Incidence of Cataract Surgery - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Incidence of Cataract Surgery in Patients Treated with Mirvetuximab Soravtansine: An Evaluation of Ocular Safety

  • By

  • Jordyn F. Silverstein

  • Alexandra Smick

  • Edmund Tsui

  • Oladunni Alomaja

  • Bridget Johnson

  • Chi-Hong Tseng

  • Ritu Salani

  • Dennis J. Slamon

  • Dana M. Chase

  • Gottfried E. Konecny

  • May 21, 2026

Share

  • 1

    Mirvetuximab soravtansine (MIRV) is associated with a high incidence of cataract surgery in patients with recurrent ovarian cancer.

  • 2

    In a matched cohort study, 42.3% of patients treated with MIRV underwent cataract surgery compared to 11.5% in non-exposed patients.

  • 3

    Adding one treatment cycle of MIRV increased the odds of cataract surgery by 21%, with 64% of patients treated for 6 months or more requiring surgery.

  • 4

    The study suggests potential delayed long-term ocular toxic effects from MIRV, as prior trials reported lower cataract rates.

  • 5

    Further research is needed to understand the mechanisms behind MIRV-associated cataracts and the role of corticosteroid eye drops.

Original Source(s)

Mirvetuximab Soravtansine Exposure and Incidence of Cataract Surgery

  • by Jordyn F. Silverstein, Alexandra Smick, Edmund Tsui, Oladunni Alomaja, Bridget Johnson, Chi-Hong Tseng, Ritu Salani, Dennis J. Slamon, Dana M. Chase, Gottfried E. Konecny

  • May 21, 2026

Related Content

Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Intraoperative Evaluation of Sarcoma Surgical Margins With Indocyanine Green Fluorescence Imaging: Results From an Observational Study

Does active surveillance prior to radical prostatectomy increase the risk of adverse pathological findings or postoperative prostate cancer treatment?